Androgen receptor action in hormone-dependent and recurrent prostate cancer

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 362-372

  Agoulnik, Irina U ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen receptor; Cell signaling; Co activator; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; LIGAND; PROSTATE SPECIFIC ANTIGEN; REGULATOR PROTEIN;

ANTIGEN EXPRESSION; CANCER HORMONE THERAPY; GENE CONTROL; HORMONAL REGULATION; HORMONE DEPENDENCE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION;

ANDROGENS; ANIMALS; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; MALE; MODELS, BIOLOGICAL; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 33748949049     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20811     Document Type: Review

References (51)

1. Agoulnik IU, Krause WC, Bingman WE, Rahman HT, Amrikachi M, Ayala GE, Weigel NL. 2003. Repressors of androgen and progesterone receptor action. J Biol Chem 278:31136-31148.
2. Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. 2005. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959-7967.
3. Arnold JT, Isaacs JT. 2002. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 9:61-73.
4. Balk SP. 2002. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-139.
5. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, De Falco A, Varricchio L, Bottero D, Nanayakkara M, Migliaccio A, Auricchio F. 2004. Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids 69:517-522.
6. Chang CY, Walther PJ, McDonnell DP. 2001. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61:8712-8717.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
8. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285
9. [Comment in Nat Med;5(3):264-265, 1999].
10. Debes JD, Tindall DJ. 2002. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 187:1-7.
11. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
12. Debes JD, Sebo TJ, Lohse CM, Murphy LM, de Haugen AL, Tindall DJ. 2003. p300 in prostate cancer proliferation and progression. Cancer Res 63:7638-7640.
13. Edwards J, Bartlett JMS. 2005a. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 95:1320-1326.
14. Edwards J, Bartlett JMS. 2005b. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95:1327-1335.
15. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
16. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SAW, Jaffray E, Hay RT, Palvimo JJ, Jänne OA, Pestell RG. 2002. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22:3373-3388.
17. Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. 2004. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer 3:98-103.
18. Gioeli D. 2005. Signal transduction in prostate cancer progression. Clin Science 108:293-308.
19. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001a. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
20. Gregory CW, Johnson RTJ, Mohler JL, French FS, Wilson EM. 2001b. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898.
21. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119-7130.
22. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM. 2001. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276:11204-11213.
23. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, DeMayo FJ, Tilley W, Greenberg NM. 2005. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156.
24. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: An overview. Endocr Rev 23:175-200.
25. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. 2004. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227.
26. Huang WC, Chen CC. 2005. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25:6592-6602.
27. Huggins C, Stephens RC, Hodges CV. 1940. Studies on prostatic cancer: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209.
28. Jonas BA, Privalsky ML. 2004. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem 279:54676-54686.
29. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. 2003. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 22:781-796.
30. Lee MS, Igawa T, Lin MF. 2004. Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells. Oncogene 23:3048-3058.
31. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. 2004. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 28:928-934.
32. Lin H-K, Wang L, Hu Y-C, Altuwaijri S, Chang C. 2002. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048.
33. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. 2003. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902-50907.
34. Linja MJ, Visakorpi T. 2004. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92:255-264.
35. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T. 2004. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10:1032-1040.
36. Lu S, Jenster G, Epner DE. 2000. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: Role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14:753-760.
37. Lu S, Ren C, Liu Y, Epner DE. 2006. PI3K-Akt signaling is involved in the regulation of p21WAF/CIP expression and androgen-independent growth in prostate cancer cells. Int J Oncol 28:245-251.
38. McEwan IJ. 2004. Molecular mechanisms of androgen receptor-mediated gene regulation: Structure-function analysis of the AF-1 domain. Endocr Relat Cancer 11:281-293.
39. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527.
40. Miyamoto H, Rahman M, Takatera H, Kang H-Y, Yeh S, Chang H-C, Nishimura K, Fujimoto N, Chang C. 2002. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 277:4609-4617.
41. Mohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, Wilson EM. 2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448.
42. Smith CL, O'Malley BW. 2004. Coregulator funtion: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71.
43. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J, Shapiro E, Garabedian MJ, Logan SK. 2005. Cell specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 280:40916-40924.
44. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. 2002. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
45. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. 2004. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64:7156-7168.
46. Walcott JL, Merry DE. 2002. Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm 65:127-147.
47. Weber MJ, Cioeli D. 2004. Ras signaling in prostate cancer progression. J Cell Biochem 91:13-25.
48. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley BW. 1998. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-1925.
49. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
50. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai M-J. 2003. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742-7755.
51. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai M-J. 2005. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65:7976-7983.